Impact of time to relapse (TTR) and metastasectomy (MTS) on survival in leiomyosarcoma (LMS): A CanSaRCC study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth ...
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in ...
Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...
In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.
Recent studies indicate that the hyperactivation of the PD-1/PD-L1 axis in Alzheimer’s disease (AD) brain has an influence on disease pathophysiology. With this in mind, researchers from Sungkyunkwan ...
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, ...
This is a randomized, multicenter, pivotal study designed to evaluate the efficacy and safety of IBI363 monotherapy versus pembrolizumab monotherapy in patients with unresectable, locally advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback